logo
Hong Kong's IPO market is on fire — here's what's fueling the surge

Hong Kong's IPO market is on fire — here's what's fueling the surge

CNBC11 hours ago
Investors and businesses' enthusiasm for Hong Kong's equity capital markets is roaring back, as Chinese companies flocked to the city for fundraising, sparking a frenzy in the market that had been forsaken in recent years.
Outsized deals and a state-backed push for companies listed in the mainland exchanges to seek a listing in Hong Kong have thrust capital-raising volume to the strongest first half-year since 2021, according to data from data provider Dealogic.
New listing volumes on the Hong Kong Stock Exchange jumped around eight times to $14 billion in the first half of this year, from just $1.8 billion in the same period in 2024, according to Dealogic. That excluded SPAC listings, or special purpose acquisition companies established solely to raise capital through an IPO, with the aim of eventually acquiring or merging with another company.
That puts the city on track to become the world's largest listing destination this year, surpassing the Nasdaq and the New York Stock Exchange. PwC projected up to 100 IPOs in Hong Kong this year, with total fundraising to exceed $25.5 billion.
The frenzy came after years of lackluster IPO activity in the city amid post-pandemic risk-off sentiment and stuttering economic growth.
In the first half of this year, there were 43 new listings in Hong Kong, with proceeds topping $13.6 billion, surpassing the total sum raised in 2024, data from financial data platform Wind Information showed.
In comparison, there were only 73 listings in 2023, raising just $5.9 billion, according to HKEX data.
The renewed interest is fueled by a confluence of factors, including Beijing's regulatory tailwinds, the muted pace of A-share listings, ample market liquidity, and delisting fears in U.S. markets, driving mainland companies to raise funds in Hong Kong, according to Steven Sun, head of China equity strategy at HSBC.
"The IPO boom in the Hong Kong market is certainly driven by dual-listing of A-then-H [shares]," said Sun. A-shares refer to mainland-listed shares, while H-shares are those listed in Hong Kong.
"More and more companies use the proceeds to fund their globalization strategy," Sun said, as the Hong Kong dollar is more fungible than the Chinese yuan in global markets.
A jump in Chinese equity prices last September, triggered by expectations of stronger economic stimulus, helped turn the tide on bearish narratives about China.
At the start of this year, the release of DeepSeek's low-cost but powerful model further fueled a rally in Chinese tech stocks as investors began to reassess China's capacity for innovation, spurring a rerating of Chinese equities.
"Market valuations broadly have improved back to historical average levels, which provides a better backdrop for companies looking to fundraise," said Eugene Hsiao, head of China equity strategy at Macquarie.
As of Wednesday's close, Hong Kong's Hang Seng index has gained a stellar 21% so far this year, making it one of the best-performing major markets globally.
Hopes that Chinese authorities will likely unleash additional fiscal spending to shield the economy from any trade-related shock have further underpinned business and investors' confidence.
In an apparent shift to support the private sector, Chinese President Xi Jinping told the nation's top business leaders in February that the country needs their help to deliver economic growth.
That shift, coupled with the long-awaited approval by Beijing for mainland firms to list offshore, unleashed a wave of pent-up demand, particularly for high-quality, consumer-facing companies that are less exposed to geopolitical headwinds, said Lorraine Tan, director of equity research at Morningstar.
Chinese securities regulator last year issued a slew of measures aimed at fast-tracking approval for eligible mainland tech companies to list in Hong Kong. Hong Kong regulators also launched a so-called "Technology Enterprises Channel" in May to facilitate IPO approvals for specialist technology and biotech companies, particularly those already listed in the mainland.
"Policy encouraging leading corporate citizens to list in Hong Kong have provided a much-needed shot in the arm" in reviving IPO activity in the city, said Perris Lee, head of equity capital market at Dealogic.
Another driver for Hong Kong's market rally has been the ample liquidity provided by mainland investors piling into Hong Kong shares, chasing an artificial intelligence frenzy sparked by Deepseek's breakthroughs and tapping into major capital-raising deals.
The southbound net inflows, tracked through the cross-border link Stock Connect scheme, surged to a record high in the April-June quarter, since the scheme was launched in 2014, according to Wind Information.
In stark contrast, China's benchmark CSI 300 has barely budged this year, up 0.2% year to date, according to LSEG data.
That has prompted onshore investors to shift money to Hong Kong-listed equities, bolstering the Southbound inflows to account for nearly half of Hong Kong's daily stock turnover, according to Sun's estimates.
These factors helped push a flurry of mainland China-traded companies to seek secondary listing in Hong Kong, including battery maker Contemporary Amperex Technology.
Already listed in Shenzhen, the company raised more than $5 billion in a secondary listing in Hong Kong in May, in what is the world's biggest such offering so far this year.
Additionally, Hong Kong's market is more "inclusive" of emerging sectors, like AI, renewable energy, digital consumption and biotech, which align with mainland firms' needs, said Wei Li, head of multi-asset investments for China at BNP Paribas.
Among the over 200 active IPO applicants in the pipeline to be listed on HKEX, over 40 are companies already listed on mainland stock exchanges, Wind Information showed.
Other high-profile companies that have sought a primary listing in Hong Kong this year include bubble tea retailers Mixue Group, Guming Holding and ride-hailing platform operator Caocao Inc.
A Hong Kong listing for Chinese companies would also aid their global expansion plans.
Amid cutthroat competition at home and flared-up trade tensions with the U.S., Beijing has called on its leading companies to expand globally and diversify their manufacturing locations.
"The appetite to raise offshore funds, especially in HKD, is a reflection of broader plans to expand into overseas markets," said Hsiao.
The heightened U.S.-China tensions have made Hong Kong a preferred IPO destination for many Chinese firms, over concerns that the Trump administration could order a delisting from U.S. exchanges.
"A secondary listing essentially provides extra insurance for U.S.-listed Chinese companies in an unlikely event that a delisting becomes unnegotiable," said Lee, suggesting that companies are likely to have engaged financial advisors to hammer out a "plan B," with or without delisting.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Like Google, China's biggest search player Baidu is beefing up its product with AI to fight rivals
Like Google, China's biggest search player Baidu is beefing up its product with AI to fight rivals

CNBC

time12 minutes ago

  • CNBC

Like Google, China's biggest search player Baidu is beefing up its product with AI to fight rivals

Chinese tech giant Baidu has bolstered its core search platform with artificial intelligence in the biggest overhaul of the product in 10 years. Analysts told CNBC the move was a bid to keep ahead of fast-moving rivals like DeepSeek, rather than traditional search players. "There has been some small pressure on the search business but the focus on AI and Ernie Bot is a key move ahead," Dan Ives, global head of tech research at Wedbush Securities, told CNBC by email. Ernie Bot is Baidu's AI chatbot. "Baidu is not waiting around to watch the paint dry, full steam ahead on AI," he added. Baidu is China's biggest search engine, but — as is also being seen by Google — the search market is being disrupted. Users are flocking instead to AI services such as ChatGPT or DeepSeek, which shocked the world this year with its advanced model it claimed was created at a fraction of the cost of rivals. But Kai Wang, Asia equity market strategist at Morningstar, also noted that short video platforms such as Douyin and Kuaishou are also getting into AI search and piling pressure on Baidu. To counter this, Baidu made some major changes to its core search product: "This is more aligned with how people use ChatGPT and DeepSeek in terms of how they look for answers," Wang said. Outside of China, Google has also been looking to enhance its core search product with AI, highlighting how search has been under pressure from the burgeoning technology. Baidu was one of China's first movers when it came to AI, releasing its first models and ChatGPT-style product Ernie Bot to the public in 2023. Since then, it has aggressively launched updated AI models. However, the Beijing-headquartered company has also faced intense competition from fellow tech giants like Alibaba and Tencent, as well as upstarts such as DeepSeek. These companies have also been launching new models and infusing AI into their products and Baidu's stock has fallen behind as a result. Baidu shares have risen around 2.5% this year, versus a 30.5% surge for Alibaba and a 20% rise for Tencent. "This is a defensive and offensive move ... Baidu needs to be aggressive and perception-wise show they are not the little brother to Tencent on the AI front," Wedbush Securities' Ives added.

INOVIO Announces Pricing of $25 Million Public Offering
INOVIO Announces Pricing of $25 Million Public Offering

Associated Press

time27 minutes ago

  • Associated Press

INOVIO Announces Pricing of $25 Million Public Offering

PLYMOUTH MEETING, Pa., July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock and accompanying Series A warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.75 per share of common stock and Series B warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.75 per share of common stock, at a combined public offering price of $1.75 per share of common stock and accompanying Series A and Series B warrants. All of the securities in the offering are being sold by INOVIO. The offering is expected to close on or about July 7, 2025, subject to the satisfaction of customary closing conditions. INOVIO also granted the underwriters an option for a period of 30 days to purchase up to 2,142,857 additional shares of the Company's common stock and Series A warrants to purchase up to 2,142,857 additional shares of its common stock and Series B warrants to purchase up to 2,142,857 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by INOVIO, excluding any exercise of the underwriters' option to purchase additional securities and assuming no exercise of the accompanying Series A and Series B warrants, are expected to be approximately $25 million. Piper Sandler & Co. is acting as sole active book-running manager for the offering. Oppenheimer & Co. Inc. is also acting as a passive bookrunner for the offering. A shelf registration statement relating to the shares of common stock and accompanying Series A and Series B warrants offered in the offering described above was filed with the Securities and Exchange Commission ('SEC') on November 9, 2023 and declared effective by the SEC on January 31, 2024. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC and are available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by telephone at (800) 747-3924, or by e-mail at [email protected] and Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, or by telephone at (212) 667-8055, or by e-mail at [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. Forward-Looking Statements This release contains or may imply 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the public offering of INOVIO's securities, including the timing of the closing of the offering, as well as the anticipated proceeds of the offering. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in INOVIO's Annual Report on Form 10-K for the year ended December 31, 2024, INOVIO's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. Contacts Media: Jennie Willson (267) 429-8567 [email protected] Investors: Peter Vozzo, ICR Healthcare, 443-213-0505 [email protected] View original content to download multimedia: SOURCE INOVIO Pharmaceuticals, Inc.

AST SpaceMobile Secures Additional $100.0 Million of Liquidity from Non-Dilutive Equipment Financing
AST SpaceMobile Secures Additional $100.0 Million of Liquidity from Non-Dilutive Equipment Financing

Associated Press

time27 minutes ago

  • Associated Press

AST SpaceMobile Secures Additional $100.0 Million of Liquidity from Non-Dilutive Equipment Financing

MIDLAND, Texas--(BUSINESS WIRE)--Jul 3, 2025-- AST SpaceMobile, Inc. ('AST SpaceMobile') (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, designed for both commercial and government applications, today announced the closing of a $100.0 million equipment financing facility led by Trinity Capital Inc. (NASDAQ: TRIN) ('Trinity'), a leading alternative asset manager. This non-dilutive financing is designed to support AST SpaceMobile's accelerated manufacturing and network deployment goals during 2025 and 2026. 'This new non-dilutive financing enables AST SpaceMobile to continue its strong momentum executing against its accelerated operational plans,' said Andrew Johnson, Chief Financial Officer of AST SpaceMobile. 'This facility is the first such type of financing agreement for the company and reflects our stage of rapid growth and transition from Research & Development to full-scale manufacturing and network deployment.' This non-dilutive financing provides an additional $100.0 million of long-term liquidity, including $25.0 million drawn at closing against previously purchased equipment, available through 2031. The facility uses existing and planned equipment as collateral and is designed to fit into a more mature, long-term capital structure, facilitating future debt capital, enabling flexibility and facilitating continued growth. The company's capital structure continues to mature through a robust funding strategy, demonstrated by the successful convertible note issuance in January 2025, the retirement of approximately half the convertible notes after a share price increase of over 100% within six months, the diligent and prudent use of the 2025-issued At-the-Market facility, while concluding the second quarter with over $900.0 million in cash, cash equivalents, and restricted cash. About AST SpaceMobile AST SpaceMobile is building the first and only global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on our extensive IP and patent portfolio, and designed for both commercial and government applications. Our engineers and space scientists are on a mission to eliminate the connectivity gaps faced by today's five billion mobile subscribers and finally bring broadband to the billions who remain unconnected. For more information, follow AST SpaceMobile on YouTube, X (formerly Twitter), LinkedIn and Facebook. Watch this video for an overview of the SpaceMobile mission. About Trinity Capital Inc. Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies. With five distinct business verticals–Sponsor Finance, Equipment Finance, Tech Lending, Asset-Based Lending, and Life Sciences–Trinity Capital stands as a long-term trusted partner for innovative companies seeking tailored debt solutions. Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and in London (UK). For more information on Trinity Capital, please visit and stay connected to the latest activity via LinkedIn and X (@trincapital). Forward-Looking Statements This communication contains 'forward-looking statements' that are not historical facts, and involve risks and uncertainties that could cause actual results of AST SpaceMobile to differ materially from those expected and projected. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believes,' 'estimates,' 'anticipates,' 'expects,' 'intends,' 'plans,' 'may,' 'will,' 'would,' 'potential,' 'projects,' 'predicts,' 'continue,' or 'should,' or, in each case, their negative or other variations or comparable terminology. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside AST SpaceMobile's control and are difficult to predict. Factors that could cause such differences include, but are not limited to: (i) expectations regarding AST SpaceMobile's strategies and future financial performance, including AST's future business plans or objectives, expected functionality of the SpaceMobile Service, anticipated timing of the launch of the Block 2 BlueBird satellites, anticipated demand and acceptance of mobile satellite services, prospective performance and commercial opportunities and competitors, the timing of obtaining regulatory approvals, ability to finance its research and development activities, commercial partnership acquisition and retention, products and services, pricing, marketing plans, operating expenses, market trends, revenues, liquidity, cash flows and uses of cash, capital expenditures, and AST SpaceMobile's ability to invest in growth initiatives; (ii) the negotiation of definitive agreements with mobile network operators relating to the SpaceMobile Service that would supersede preliminary agreements and memoranda of understanding and the ability to enter into commercial agreements with other parties or government entities; (iii) the ability of AST SpaceMobile to grow and manage growth profitably and retain its key employees and AST SpaceMobile's responses to actions of its competitors and its ability to effectively compete; (iv) changes in applicable laws or regulations; (v) the possibility that AST SpaceMobile may be adversely affected by other economic, business, and/or competitive factors; (vi) the outcome of any legal proceedings that may be instituted against AST SpaceMobile; and (vii) other risks and uncertainties indicated in the Company's filings with the Securities and Exchange Commission (SEC), including those in the Risk Factors section of AST SpaceMobile's Form 10-K filed with the SEC on March 3, 2025 and Form 10-Q filed with the SEC on May 12, 2025. AST SpaceMobile cautions that the foregoing list of factors is not exclusive. AST SpaceMobile cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors in AST SpaceMobile's Form 10-K filed with the SEC on March 3, 2025 and Form 10-Q filed with the SEC on May 12, 2025. AST SpaceMobile's securities filings can be accessed on the EDGAR section of the SEC's website at Except as expressly required by applicable securities law, AST SpaceMobile disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. View source version on CONTACT: Investor Contact:Scott Wisniewski [email protected] Contact:Allison Eva Murphy Ryan 917-547-7289 [email protected] KEYWORD: UNITED STATES NORTH AMERICA TEXAS INDUSTRY KEYWORD: TECHNOLOGY MOBILE/WIRELESS AEROSPACE MANUFACTURING 5G OTHER COMMUNICATIONS OTHER TECHNOLOGY PUBLIC RELATIONS/INVESTOR RELATIONS TELECOMMUNICATIONS NETWORKS COMMUNICATIONS INTERNET OTHER MANUFACTURING SATELLITE SOURCE: AST SpaceMobile, Inc. Copyright Business Wire 2025. PUB: 07/03/2025 07:30 AM/DISC: 07/03/2025 07:30 AM

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store